---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-117794"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2026-03-20T23:59:59+00:00"
generated_at: "2026-05-15T09:29:40.799094+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics receives two Nasdaq deficiency notices with 180-day cure periods

## Summary
- Bid Price Notice: common stock closing bid below $1.00 for 30 consecutive business days; cure by Sept 14, 2026.
- MVLS Notice: market value of listed securities below $50M for 30 consecutive business days; cure by Sept 14, 2026.
- To regain compliance, bid price must close at $1+ for 10 consecutive days, or MVLS at $50M+ for 10 consecutive days.
- If not cured by deadline, company may transfer to Nasdaq Capital Market or face delisting.
- Stock continues trading on Nasdaq under symbol QNCX during cure period.

## SEC filing metadata
- accession: 0001193125-26-117794
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2026-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312526117794/0001193125-26-117794-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312526117794/d122428d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-117794
- JSON: https://secwatch.observer/filing/0001193125-26-117794.json
- Plain text: https://secwatch.observer/filing/0001193125-26-117794.txt

## Key facts
- Listing & Compliance Notices
  Quince Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: March 16, 2026, Quince Therapeutics, Inc. (the “Company”) received a notice (the “Bid Price Notice”) from the Nasdaq Listing Qualifications department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the closing bid price of the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Company has a period of 180 calendar days, or until September 14, 2026 (the “Compliance Date”), to regain compliance with the Minimum Bid
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312526117794/0001193125-26-117794-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.